What It's Like To Advance A Cell Therapy Through The Japan Entry Acceleration Program
By Sanjeev Luther, president & CEO, Ernexa Therapeutics
When Ernexa Therapeutics became one of only 10 companies worldwide to join the Japan Entry Acceleration Program (JEAP), it marked more than a milestone for our organization. It signaled a meaningful opportunity to engage with one of the most advanced and forward-thinking regenerative medicine ecosystems in the world.
For companies working at the frontier of cell therapy, the path from scientific innovation to global clinical impact is rarely linear. It requires not only strong science but also thoughtful engagement with regulatory environments, manufacturing ecosystems, clinical collaborators, and, critically, patients and clinicians across diverse healthcare systems. JEAP offers a structured, highly supported entry point into Japan’s regenerative medicine landscape, and our early experience has underscored both the rigor and the openness of that ecosystem.
A Highly Competitive Global Selection Process
JEAP, launched by the Japan External Trade Organization (JETRO), is designed to accelerate the entry of promising international regenerative medicine companies into Japan. The inaugural cohort drew approximately 70 companies from 25 countries, spanning a wide range of therapeutic modalities and development stages. Being selected to the final 10 was both humbling and validating for our team.
We believe our selection reflects the strength of our differentiated cell therapy platform and the potential of our pipeline to address significant unmet needs in oncology and autoimmune disease. In particular, Japan’s leadership in regenerative medicine and its progressive regulatory framework create a compelling environment for innovative approaches such as ours.
Our programs — ERNA-101, designed to activate the immune system’s ability to recognize and attack tumors, and ERNA-201, aimed at restoring immune balance in autoimmune disease — align closely with Japan’s focus on translational science and precision medicine. As we prepare to advance ERNA-101 into first-in-human clinical studies in ovarian cancer, the opportunity to engage with Japanese stakeholders adds an important dimension to our global development strategy.
Early Engagement: Structured, Practical, And Deeply Collaborative
One of the most notable aspects of JEAP has been the structure and depth of engagement. From the outset, the program has provided a combination of strategic mentorship, regulatory insight, and hands-on introductions to key stakeholders across Japan’s regenerative medicine ecosystem.
Rather than offering a generalized overview of the market, JEAP has emphasized practical, company-specific guidance. This includes tailored discussions around Japan’s regulatory pathways for regenerative medicine products, clinical development considerations specific to the Japanese patient population, and commercialization dynamics that differ meaningfully from Western markets.
The mentorship component has been particularly valuable. Engaging directly with experienced Japanese industry leaders, regulatory experts, and academic collaborators has allowed us to refine our thinking around potential development pathways and partnership structures. These conversations were grounded in real-world experience, helping us navigate Japan’s highly structured yet innovation-friendly regulatory environment.
Access To A Unique Ecosystem Of CDMOs And CROs
A distinguishing feature of JEAP is its ability to facilitate direct engagement with Japan’s leading CDMOs and CROs. For a cell therapy company like Ernexa, where manufacturing scalability and clinical execution are central to success, these interactions are particularly important.
We have had the opportunity to visit and engage with organizations deeply embedded in Japan’s regenerative medicine infrastructure. What stands out is not only their technical capability but their commitment to quality, precision, and long-term collaboration.
For our platform, which is based on engineered induced pluripotent stem cells (iPSCs) differentiated into induced mesenchymal stem cells (iMSCs), scalable and reproducible manufacturing is essential. Japan’s CDMO ecosystem is uniquely positioned to support this type of advanced cell therapy development, and JEAP has helped us begin meaningful dialogues in this area.
Japan’s Regulatory Environment: Predictability And Innovation Coexist
One of the most consistent themes throughout our engagement has been the clarity and predictability of Japan’s regulatory environment for regenerative medicine. Japan has established a framework that is both rigorous and innovation-enabling, particularly for cell-based therapies.
This balance is critical because early-stage cell therapies require regulatory pathways that are scientifically robust yet flexible enough to accommodate evolving modalities. Japan’s system — built in part to accelerate access to regenerative therapies for patients with high unmet need — provides an important complement to regulatory frameworks in the United States and Europe.
Through JEAP, we have gained a more nuanced understanding of how early scientific engagement with regulators can shape development strategy, potentially accelerating timelines while maintaining safety and efficacy standards.
Strategic Value Beyond Market Entry
While JEAP is structured as a market entry program, its value extends far beyond geographic expansion. For Ernexa, participation informs how we think about global development strategy more broadly.
First, it reinforces the importance of building therapies that are globally relevant from the outset. Diseases such as ovarian cancer and autoimmune conditions do not respect geographic boundaries, and neither should the design of next-generation therapies.
Second, it highlights the value of early cross-border collaboration in shaping clinical and manufacturing strategies. Engaging with Japanese stakeholders at this stage of development allows us to consider how our programs might be adapted or optimized for different healthcare environments without compromising scientific integrity.
Finally, it strengthens our conviction that collaboration, rather than isolated development, is increasingly essential in cell therapy. The complexity of these modalities demands integrated ecosystems that span academia, industry, regulators, and clinical providers.
Reinforcing Our Mission Through Global Collaboration
Participation in JEAP has reinforced the global relevance of our mission to develop transformative cell therapies that can meaningfully change outcomes for patients facing serious diseases. The discussions we are having in Japan are not just about market entry; they are about how innovative therapies can be developed, evaluated, and ultimately delivered in ways that are both scientifically rigorous and patient-centered.
There is a shared recognition among JEAP participants and Japanese stakeholders that regenerative medicine is entering a new phase — one defined not only by scientific breakthroughs but by the ability to translate those breakthroughs into accessible, scalable treatments.
Building On Early Momentum
While we are still early in our engagement with JEAP, the program has already begun to shape how we think about collaboration, development strategy, and global expansion.
In the coming months, we look forward to deepening our interactions with potential clinical, manufacturing, and academic partners in Japan, including leading oncology experts who are exploring next-generation approaches to ovarian cancer. We also anticipate further refining our understanding of how ERNA-101 and ERNA-201 could integrate into Japan’s clinical landscape, particularly in oncology and autoimmune disease settings where unmet need remains significant.
Additionally, we had the opportunity to engage in discussions about potential clinical collaborations in ovarian cancer with renowned oncologist Toshihiko Doi, MD, Ph.D., director of the National Cancer Center Hospital East in Japan. Dr. Doi is widely recognized for his leadership in oncology clinical development and translational research, and these conversations further underscore the depth of expertise and collaborative potential within Japan’s oncology ecosystem. As ERNA-101 advances toward first-in-human clinical studies in ovarian cancer, engagement with respected clinical leaders in Japan provides valuable perspective on how innovative cell therapies may ultimately be evaluated and integrated into clinical practice globally.
Importantly, we see JEAP not as a stand-alone initiative but as part of a broader ecosystem of global engagement that will be essential to advancing cell therapy innovation. The relationships and insights gained through this program will inform our strategy well beyond Japan.
Being selected for JEAP has provided Ernexa with a unique window into one of the world’s most advanced regenerative medicine ecosystems. More importantly, it has offered a platform for meaningful dialogue, collaboration, and learning at a critical stage in our development.
As we continue to advance our pipeline and prepare for clinical milestones ahead, we remain committed to building therapies that are not only scientifically differentiated but also globally relevant and accessible. Programs like JEAP reinforce that this goal is best achieved through collaboration — across borders, disciplines, and institutions.
About The Author:
Sanjeev Luther is the president and CEO of Ernexa Therapeutics and a member of the board of directors. Sanjeev is a seasoned pharmaceutical executive with over 30 years in leadership roles at organizations including Cornerstone Pharmaceuticals, Bristol Myers Squibb, Novartis, Bausch and Lomb, and GE Healthcare. Ernexa Therapeutics is developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease.